In the last decade, the management of Type 2 diabetes (T2DM) has evolved significantly with the introduction of novel antidiabetic medications, notably sodium–glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1RAs). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.